The biological characteristics that c-Myc is expressed only in cycling cells (Prochownik, 2004) and the fact that only transient inhibition is sufficient to cause tumor regression (Hart et al., 2014; Yu et al., 2016; Vaseva et al., 2018; Singh et al., 2022) make c-Myc to be an attractive target for cancer therapy. The gene discussed is MYC; the disease is neoplasm.